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Abstract
Background:  Evidence for an increased prevalence of candidaemia and for high associated
mortality in the 1990s led to a number of different recommendations concerning the management
of at risk patients as well as an increase in the availability and prescription of new antifungal agents.
The aim of this study was to parallel in our hospital candidemia incidence with the nature of
prescribed antifungal drugs between 1993 and 2003.
Methods: During this 10-year period we reviewed all cases of candidemia, and collected all the
data about annual consumption of prescribed antifungal drugs
Results: Our centralised clinical mycology laboratory isolates and identifies all yeasts grown from
blood cultures obtained from a 3300 bed teaching hospital. Between 1993 and 2003, 430 blood
yeast isolates were identified. Examination of the trends in isolation revealed a clear decrease in
number of yeast isolates recovered between 1995–2000, whereas the number of positive blood
cultures in 2003 rose to 1993 levels. The relative prevalence of Candida albicans and C. glabrata was
similar in 1993 and 2003 in contrast to the period 1995–2000 where an increased prevalence of C.
glabrata was observed. When these quantitative and qualitative data were compared to the amount
and type of antifungal agents prescribed during the same period (annual mean defined daily dose:
2662741; annual mean cost: 615629 €) a single correlation was found between the decrease in
number of yeast isolates, the increased prevalence of C. glabrata and the high level of prescription
of fluconazole at prophylactic doses between 1995–2000.
Conclusion: Between 1993 and 2000, the number of cases of candidemia halved, with an increase
of C. glabrata prevalence. These findings were probably linked to the use of Fluconazole prophylaxis.
Although it is not possible to make any recommendations from this data the information is
nevertheless interesting and may have considerable implications with the introduction of new
antifungal drugs.
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Background
Bloodstream infections are a major cause of morbidity
and mortality in developed countries. Recent statistics in
the USA show that these infections are the tenth leading
cause of death overall [1]. Their true incidence remains
unknown, but it is estimated that around 250 000 cases
occur annually in the USA alone [2]. In France, the preva-
lence of septicaemia in the hospital environment has been
estimated to be around 0.4% [3]. Infections due to Cand-
ida species are an increasingly important complication in
hospitalised patients [4-6]. North American and Euro-
pean surveillance studies have provided recommenda-
tions about the definition of risk factors and
epidemiology of candidaemia [7,8]. Large scale epidemi-
ological studies conducted in Europe [9] and the USA [10]
show that Candida species are now the fourth most com-
mon cause of hospital-acquired bloodstream infection
[11]. Candida albicans is the most common cause of candi-
daemia, and in general has remained susceptible in vitro to
both polygenic drugs and fluconazole (FCZ) [12,13]. As
the use of FCZ has increased, however, it has become
more important to screen for azole resistance among
bloodstream isolates or an increase in frequency of blood-
stream infection due to species other than C. albicans,
which have a higher incidence of in vitro azole resistance
(e.g., C. glabrata and C. krusei) [14,15]. In this study, a lon-
gitudinal surveillance of bloodstream infections caused
by Candida species was carried out in a 3300 bed teaching
hospital during the 10-year period 1993–2003. The
results were correlated with the use of FCZ over the same
period.
Methods
Mycological investigations
A retrospective study of positive blood cultures for Cand-
ida species between 1993–2003 was carried out by the
mycology service. This study allowed us to determine the
number of cases of candidaemia annually; candidaemia
was defined as one or more positive blood cultures for
Candida species isolated from patients with clinical signs
of infection. During this period three blood culture sys-
tems were used: Bio Argos (Sanofi Diagnostics Pasteur,
Marnes-la-Coquette, France) and BactAlert 3D (Organon
Teknika, France) were used successively by the bacteriol-
ogy laboratory for the isolation of microorganisms in
cases of septicaemia. When yeasts were isolated, the strain
was transferred to the mycology laboratory for identifica-
tion. In parallel, the Bactec 9050 system with aerobic
mycosis IC/F medium (Becton Dickinson, USA) has been
used by the mycology laboratory since November 1999.
Mycosis IC/F medium, which is specifically adapted for
the growth of fungi, significantly reduces the mean time
for yeast detection(in particular C. albicans and C. gla-
brata) [16].
For all blood culture systems, the blood culture flasks
were mixed with 10 ml of blood and then incubated at
37°C for 7 days. A control for microbial growth was car-
ried out automatically.
Identification of strains
Positive samples were examined directly after staining
with Giemsa or toluidine blue and subculture on Sabour-
aud's agar containing gentamycin (40 mg/L). All strains
isolated were identified using the germ tube test, chlamy-
dospore production and API 32C system (Bio-Mérieux,
Marcy l'Etoile, France). Since 1997, all strains have also
been subcultured on chromogenic medium CHROMagar,
which allows the presumptive identification of some Can-
dida species. The germ tube test has been replaced with
Bichrolatex albicans, a rapid immunological test for the
identification of C. albicans.
Pharmaco-economic investigations
The annual consumption of antifungal drugs during the
same period was determined from pharmacy data (TAGE,
GEF, and Mc Kesson softwares). The annual consumption
of a drug takes into account all hospital services using the
drug, with any eventual returns of the product deducted.
This consumption is expressed as total milligrams of
active drug used. The antifungal drugs included in the
evaluation were indicated for either prophylaxis or cura-
tive treatment of candidaemia: 5-fluorocytosine (5FC;
Ancotil®), amphotericin B (AMB; Fungizone®), amphoter-
icin B lipid complex (ABLC; Abelcet®), liposomal ampho-
tericin B (AMBD; AmBisome®), caspofungin (CAS;
Cancidas®), voriconazole (VCZ; Vfend®) and fluconazole
(FCZ; Triflucan®). The data collected included antifungal
use and the number of cases of candidaemia observed
during the same period.
Results
Distribution of candidaemia cases over the study period
During the period 1993–2003, an average of 45762 blood
cultures were analysed annually by the bacteriology labo-
ratory and an average of 659 by the mycology laboratory.
Among these, 430 (1/1000; 0.1%) were positive for Can-
dida species compared with 11% for bacteria. The cases of
candidaemia originated most frequently from the inten-
sive care service (36%), surgical unit (20%), cancer unit
(13%), gastroenterolgy (6%), haematology (6%) and pae-
diatric service (5%). The other services (burns, geriatrics,
pneumology, nephrology, internal medicine, etc.) repre-
sented only 14% of isolates overall. The annual incidence
of positive blood cultures is shown in Figure 1. Between
1995 and 2001, a decrease in number of cases of candi-
daemia was observed. In general, C. albicans was the pre-
dominant species making up 61.5% of isolates.
Conversely, a significant variation was observed for non-
albicans species, with C. glabrata predominating betweenBMC Infectious Diseases 2006, 6:80 http://www.biomedcentral.com/1471-2334/6/80
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1995 and 2001, with a peak incidence of 27% in 1997
(Figure 2). Outside this period, C. parapsilosis and C. trop-
icalis were the most frequent species isolated after C. albi-
cans. C. parapsilosis was the predominant non-albicans
species before 1995 (with a mean incidence of 14.7%),
and after 2001. The mean incidence of C. tropicalis was
9%, with a peak of 13% in 1998. Little variation was
observed for C. krusei which remained below 4%. The
other species included C. lusitaniae (n = 3), C. kefyr (n =
2), C. guilliermondii (n = 2) and C. norvegensis (n = 1). The
evolution and proportion of different Candida species in
relation to the main hospital services caring for patients at
risk of systemic candidosis is shown in Figure 3. C. albi-
cans  represented more than 60% of isolates recovered
from the different services except for oncology/haematol-
ogy where C. albicans represented only 32% of isolates.
This reduction in isolation of C. albicans was associated
with an increase in isolation of C. tropicalis (24%), C. gla-
brata (16%) and C. krusei (12%). No isolates of C. glabrata
were recovered from the paediatric service. Although the
number of strains isolated was small (n = 12), no case of
candidaemia caused by C. krusei was observed in paediat-
rics or gastroenterology.
Variation in consumption of antifungal drugs
Antifungal use in milligrams between 1993–2003 was
converted to the defined daily dose (DDD) to enable
interpretation. The DDD for the different drugs was: 70
mg for AMB, 210 mg for AMBD, 350 mg for ABLC, 400 mg
for FCZ, 10 000 mg for 5FC, 50 mg for CAS and 400 mg
for VCZ.
Figure 4 shows that different formulations of AMB were
used constantly (mean DDD 5102), with a progressive
decrease in AMB use after 1999 in favour of lipid formu-
lations (ABLC and AMBD). ABLC has been used since
1997 with a constant mean annual consumption of 647
DDD. AMBD has been used since 1998 with a considera-
ble increase in use documented since 1999. Low con-
sumption of 5FC was noted over the whole study period
(mean DDD: 425). Use of this drug, often as combined
therapy, was significant until 1995.
Evaluation of FCZ use revealed a net increase since 1997.
The mean DDD for the period 1993–1996 was 8412 com-
pared with a mean DDD of 13184 between 1997–2002.
The recent introduction of VCZ (2002) and CAS (2001)
has increased the number of drugs available to treat can-
didaemia. The large increase in use of VCZ seems to corre-
late with a reduction in FCZ use in 2003 (Figure 4). CAS
consumption is currently equivalent to that of AMBD.
Variation in consumption of fluconazole related to 
candidaemia
If FCZ consumption and profile of Candida species iso-
lated from blood cultures are superimposed it can be seen
that the increase in FCZ use correlates closely with a
change in profile of non-albicans species isolated with C.
glabrata predominating (Figure 5).
Analysis of FCZ consumption during the study period
reveals that two types of prescription were possible: low-
dose (dose between 50–100 mg) and high-dose therapy
(dose >200 mg) (Figure 6). A reduction in prescription of
lower doses was observed after 1997, coinciding with a
40% reduction in number of cases of candidaemia com-
pared to 1993 and the emergence of C. glabrata as a signif-
icant cause of infection (27%) (Figure 6). An inversion in
prescription of low- versus high-dose FCZ was observed
after 2000. During the period 1998–2000, the ratio of the
two doses was nearly 1. The relative peak in percentage of
low-dose FCZ used in 2003 corresponded to a progressive
reduction in high-dose FCZ in favour of VCZ.
Discussion
The incidence of nosocomial fungal infections has contin-
ued to rise over the past two decades in parallel with
advances in medical and surgical procedures. Bone mar-
row and solid organ transplant procedures, surgery and
medical intensive care have largely increased the number
of profoundly immunosuppressed patients at high risk of
opportunistic infection [8,11]. Invasive fungal infections
are usually severe in these patients and are difficult to
diagnose and treat [17]. A significant proportion of these
patients do not die from their underlying pathology but
die of infectious complications often related to a deep
fungal infection. Candida species are among the most fre-
Number of episodes of candidaemia recorded during 1993– 2003 in a 3300 bed French university hospital Figure 1
Number of episodes of candidaemia recorded during 1993–
2003 in a 3300 bed French university hospital.
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quently isolated agents of invasive fungal infection [18],
and account for 8–10% of hospital-acquired cases of sep-
ticaemia [15]. In spite of recent progress in antifungal
chemotherapy, the mortality rate from these infections
continues to rise [19]. Their economic impact has also
been recognised, linked largely to the empirical use of sys-
temic antifungal drugs and a prolongation of hospital stay
(on average 30 days), which is necessary for optimal treat-
ment and control of candidaemia [20,21]. This overspend
is estimated at 40.000 $ per patient in some American
intensive care units [21].
Although the procedure suffers from a lack of sensitivity,
blood culture remains an important tool in the diagnosis
of invasive candidosis [22]. According to recommenda-
tions from some experts and learned societies, a single
positive blood culture is sufficient to make a diagnosis of
invasive candidosis and justifies the initiation of antifun-
gal treatment [23]. In these conditions, epidemiological
studies on the number and type of Candida species iso-
lated from blood cultures are an important prerequisite to
developing effective antifungal strategies.
The current report presents the results of a retrospective
study of cases of candidaemia during the last decade
(1993–2003), in a French university hospital. The study
did not include patients with HIV, who were cared for in
an infectious diseases service not attached to our hospital.
Analysis of the data obtained demonstrated that the
number of cases of candidaemia halved between 1993
and 2000. This trend was probably linked to the use of
FCZ prophylaxis. The results also demonstrated that C.
albicans was the most frequently isolated species, compris-
Distribution of Candida species as bloodstream isolates by year (1993–2003) Figure 2
Distribution of Candida species as bloodstream isolates by year (1993–2003).
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ing around 60% of isolates, irrespective of the medical
specialty. These results differ from recent American stud-
ies, which reported a lower isolation rate for C. albicans of
around 50% [10]. In our study, a single exception was
noted in the oncology/haematology units where C. albi-
cans  represented less than 35% of isolates, while the
majority of isolates were species such as C. glabrata, C.
tropicalis and C. krusei which are less sensitive or resistant
to azoles. This change in epidemiology of candidaemia in
oncology/haematology confirms the results reported in a
multicentre European study where C. albicans represented
only 34.6% of isolates [9]. This emergence of non-albicans
species is probably linked to FCZ prophylaxis, which is
carried out mainly during periods of profound neutrope-
nia, particularly after allogeneic bone marrow transplan-
tation [24].
One notable finding from this investigation is the emer-
gence of C. glabrata since 1996 (Figure 2). Analysis of the
use of systemic antifungal drugs reveals an exponential
increase in FCZ use between 1993 and 2002, with an
increased use of low doses of this drug (generally used for
prophylaxis) until 1996. The emergence of C. glabrata
appears to be linked to the use of low-dose FCZ before
1997. Several reports have demonstrated that the use of
sub-optimal doses of FCZ (<400 mg) can increase the fre-
quency of C. glabrata as a cause of candidaemia in hospi-
talised patients [25,26]. It is also important to note that
the prominent use of high-dose FCZ was accompanied by
a progressive reduction in isolation of C. glabrata, which
fell to 10% of isolates in 2003. This reduction continued
with the introduction of VCZ in 2002, leading to a signif-
icant reduction in use of high-dose FCZ (Figure 6). The
low use of 5FC underlines the rarity of neuro-meningeal
mycoses in our hospital. The introduction of lipid formu-
lations of AMB has changed the use of this drug in patients
likely to develop renal failure. In particular, AMBD is used
widely as it has fewer side-effects and a broader range of
indications than ABLC [27].
Although several mechanisms of resistance to azoles
(FCZ, VCZ, ITZ) have been described in Candida, resulting
Distribution (percentage) of the most frequently isolated Candida species according to the underlying condition Figure 3
Distribution (percentage) of the most frequently isolated Candida species according to the underlying condition.
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in overexpression of CDR1/CDR2 or MDR1 genes, or
mutation in the ERG11 gene [28], the use of FCZ remains
justified. In effect, the proportion of strains of Candida
species that are resistant to FCZ remains low (<10%).
Among these, the percentage of C. glabrata strains varies
from 0–23% according to the country [15,29]. Pressure
for the selection of azole-resistant species has been
reported by several authors [28], resulting in the introduc-
tion of recommendations for good use of antifungal drugs
[18]. As far as FCZ is concerned, it has been recommended
that patients are treated with curative doses of at least 400
mg/day, and that patients are stratified justifying antifun-
gal therapy.
A reference system based on diagnostic strategies includ-
ing clinical risk factors, scores for specific signs, radiologi-
cal data and investigations based on culture of fungal
pathogens has recently been set up. Taking into account
the local ecology, the use of FCZ remains justified not just
as prophylaxis but also as curative treatment for invasive
candidosis.
The recommendations made distinguish two situations,
prophylactic treatment in patients at high risk of invasive
fungal infection, and treatment of clinically and mycolog-
ically documented invasive candidosis. The introduction
of this reference system has resulted in a 13% reduction in
cost of systemic antifungal agents (2.476.438 € in 2004
versus  2.814.617  € in 2003). Nevertheless, it does not
appear to have had a significant impact on the incidence
of candidaemia, which continues to rise (70 in 2004 vs.
38 in 1993). These data suggest that better diagnostic
monitoring is required to allow earlier identification of
patients at high risk of fungal infection. In addition to ref-
erence tests such as blood culture and histology this
approach should include other biological markers
Annual consumption of systemic antifungal agents (daily doses) between 1993–2003 Figure 4
Annual consumption of systemic antifungal agents (daily doses) between 1993–2003. AMB: amphotericin B; AMBD; ambisome; 
ABLC: abelcet; 5FC: 5-fluorocytosine; CAS: caspofungin; VCZ: voriconazole; FCZ: fluconazole.
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(inflammatory markers, determination of fungal coloni-
sation, antigens, antibodies, nucleic acid, metabolites)
whose circulation often precedes the isolation of fungi
from a sterile site. Combination of these tests should
improve the level of certainty of a fungal infection and the
early initiation of antifungal treatment, resulting in a bet-
ter prognosis. The efficacy of such measures should be
evaluated regularly and adapted to the local ecology tak-
ing into account the increase in indications for the differ-
ent drugs, the introduction of new antifungal agents and
progress in diagnostic strategies.
Conclusion
The present study reveals that the number of cases of can-
didaemia in our hospital fell by more than 50% in 1997
compared with 1993 and 2003. Analysis of antifungal use
revealed that this period corresponded to a peak in pre-
scription of oral forms of FCZ for prophylactic use. At this
time the number of isolates of C. glabrata was almost 50%
of the number of isolates of C. albicans. As C. glabrata is
known to be resistant to FCZ, it is likely that this correla-
tion is not due to chance.
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Evolution of isolation of Candida species in relation to fluconazole consumption between 1993–2003 Figure 5
Evolution of isolation of Candida species in relation to fluconazole consumption between 1993–2003.
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